Research Nester published a report titled “Heparin Market: Global Demand Analysis & Opportunity Outlook 2030” which delivers detailed overview of the global heparin market in terms of market segmentation by product, route of administration, application, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The global heparin market is estimated to grow with a CAGR of 4.1% during the forecast period 2021-2030. The market is segmented by product into unfractionated heparin (UFH), low molecular weight heparin (LMWH), and ultra low molecular weight heparin (ULMWH), out of which, the low molecular weight heparin (LMWH) segment is anticipated to garner the largest revenue of USD 5154.8 Million by the end of 2030, up from USD 3493.5 Million in 2020. The segment is also expected to hold the highest market share throughout the forecast period.
The global heparin market is expected to garner a revenue of USD 7938.6 Million by the end of 2030, up from a revenue of USD 5340 Million in 2020. Rising cases of venous thromboembolism worldwide, followed by the increasing utilization of heparin as anticoagulants, and the rapid advancements in healthcare, are some of the factors anticipated to drive the market growth during the forecast period. The market is segmented on the basis of region into North America, Europe, Asia Pacific, Latin America and Middle East & Africa region, out of which, the market in North America region is anticipated to hold the highest market share throughout the forecast period and further attain a revenue of USD 3270.7 Million by the end of 2030. Rising health expenditure in countries such as the United States and Canada, followed by the availability of a strong medical infrastructure in the countries in the region, are some of the major factors anticipated to drive the market growth. Moreover, in the year 2020, the market in the region garnered a revenue of USD 2188.2 Million in 2020. The market in the region is also anticipated to grow with a CAGR of 4.1% during the forecast period.
Growing Incidences of Deep Vein Thrombosis
Around 60,000-100,000 Americans die of deep vein thrombosis/pulmonary embolism (DVT/PE) in the United States, according to the statistics by the U.S. Centers for Disease Control and Prevention (CDC). Moreover, it has also been estimated that 1/3rd of the people would have the disease again over the next 10-year period.
Deep vein thrombosis, also known as pulmonary embolism or venous thromboembolism, is a disease related to the clotting of blood in the human body. The rising incidences of such diseases is driving the need amongst the healthcare workers to utilize anticoagulants, such as heparin, so as to lower the growing incidences. Such a factor is expected to drive the market growth during the forecast period.
However, the increasing adoption of oral anticoagulants, such as warfarin, is expected to operate as key restraint to the growth of global heparin market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global heparin market which includes company profiling of GlaxoSmithKline plc, Pfizer Inc., Aspen Holdings, Baxter International Inc., Fresenius Kabi AG, Amphastar Pharmaceuticals, Inc., Mylan N.V., Sanofi, LEO Pharma A/S, B.Braun Melsungen AG, and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global heparin market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.